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Cancer patientsAbstract Interferon-c release assay (IGRA) may improve the diagnostic accuracy for latent tuber-
culosis infection (LTBI). The aim of this study was to compare the performance of the
QuantiFERON-TB Gold-in-Tube (QFT-GIT), with the tuberculin skin test (TST) (one and two
step TST) in detection of LTBI in immunocompromised cancer patients.
The study was carried out on 50 patients and 20 healthy subjects as a control group. Patients with
active TB or AIDS were excluded. A TSTI was only positive in 2 patients (4%). The TSTII (boosterrculosis.
682 H.A. Mohammad et al.phenomena) was positive in 8 patients (16%) after 3–4 weeks. Ten patients (20%) had positive
Quantiferon test while the test was indeterminate in 14 patients (28%).
Hematological malignancy group (HMgroup) had signiﬁcantly more positive TSTII results fol-
lowed by the breast cancer group (p= 0.01). Similarly, QFT-GIT positive values were signiﬁcantly
more frequent in the HM group. This study suggests that the QFT-GIT test maintains its sensitivity
and performance in immunocompromised cancer patients, identifying a large number of truly
infected patients being anergy to the tuberculin skin test.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Tuberculosis (TB) is an important cause of morbidity and
mortality worldwide [1]. Governmental and non-governmental
organization efforts and investments have resulted in a steady
decline in disease incidence and mortality in the last decades
[2]. One third of the world population, however, has latent
tuberculosis (TB) infection (LTBI), and to reach the United
Nations Millennium Goals of eliminating the disease by
2050, it is its necessary to couple diagnosis and treatment of
active disease with new approaches to reduce this vast reser-
voir of LTBI, sufﬁcient for generating new TB cases for many
decades even if transmission was suppressed [3]. Thus, in addi-
tion to rapid, accurate, and inexpensive detection of active TB,
the detection and treatment of LTBI is also an important
strategy for TB control [1].
The speciﬁcity of the tuberculin skin test (TST) is limited by
cross-reactivity of the puriﬁed protein derivative (PPD) with
bacilli Calmette–Guerin (BCG) vaccine and with most nontu-
berculous mycobacteria (NTM). Its sensitivity is also low in
immunocompromised patients, in whom the risk of progres-
sion to TB is high. Despite these limitations, TST is routinely
used in hospital clinical practice to screen for latent TB infec-
tion [2].
Interferon-Gamma Release Assays (IGRAs) were designed
to detect the immune response to speciﬁc Mycobacterium
tuberculosis antigens, which are not present in BCG or other
nontuberculous mycobacteria. Two tests are commercially
available; one is based on the Elispot (T-SPOT.TB, Oxford
Immunotec, UK) and the other on the enzyme-linked
immunosorbent assays (ELISA) technique (QuantiFERON-
TB Gold-in-Tube, Cellestis, Australia, (QFT-GIT). Both tests
are based on the principle that the T cells of an individual who
have acquired TB infection will respond by secreting the
cytokine interferon-gamma (IFN-c) when restimulated with
M. tuberculosis antigens [4]. The US Food and Drug
Administration has approved the QFT-TB test and is evaluat-
ing the T-SPOT.TB test, which has been approved for use in
Europe. However, the performance of IGRA in various cate-
gories of immunosuppressed patients is largely unknown and
has been identiﬁed as a priority area for research [5].
Aim of the work
The aim of the study is to diagnose LTBI in immunocompro-
mised cancer patients in a hospital-based population by perfor-
mance of the Quantiferon TB test compared with TST.Patients and methods
The study was done on patients with malignancy receiving
chemotherapy in EL-Minia Oncology institute. All patients
attending oncology institute outpatient clinics were enrolled
consecutively. Patients with HIV and active tuberculosis were
excluded. The research protocol was approved by the local
ethics committee.
All participants and the control group were screened for
LTBI and TB disease at baseline. All patients were asked
about risk factors for TB including immunosuppressive
treatments, such as systemic immunosuppressive drugs
and radiotherapy, DM, and close contact to tuberculous
case.
A history of previous TB disease, recent household
exposure to an infectious TB source case and/or symptoms,
including cough for at least 2 weeks not responding to
antibiotic treatment or progressive loss of weight
was recorded. A complete physical examination was
completed.
The diagnosis of TB disease was conﬁrmed by attaining
acid-fast staining and positive culture of sputum, bronchoalve-
olar lavage ﬂuid (BALF) or pleural ﬂuid samples found to be
positive for MTB microbiologically. Information regarding
any previous Mantoux TST results and BCG vaccination, as
well as information about laboratory ﬁndings, including com-
plete blood picture (Lymphocyte counts and hemoglobin
levels) and lastly CXR ﬁndings were also recorded for all
patients at the time of enrollment. Blood samples for
QuantiFERON TB test will be collected before administration
of the Mantoux TST.
The Mantoux TST
It was performed according to the Mantoux technique.
0.1 mL of tuberculin PPD will be injected intradermally into
the volar aspect of the forearm, and the transverse induration
diameter was measured 48–72 h later. The TST results were
interpreted according to the level of risk, as reported in cur-
rent guidelines [6]. TST was performed using 5 international
units of puriﬁed protein derivative (Biocine Test; Chiron;
Siena, Italy). A TST result was considered positive if the skin
induration was P10 mm. If the result for the ﬁrst test was
negative, the test was administered again one-to-three weeks
later (the 2-step TST), and that result was considered deﬁni-
tive. If the second test is negative this means the individual is
not infected.
Table 1 Comparison between cases and controls regarding
base line data.
Assay results Patients N= 50 Controls N= 20 P
Age 40.2 ± 20.3 31.7 ± 8.8 0.07
Sex 0.1
Male 22(44%) 5(25%)
Female 28 (56%) 15(75%)
Residence 0.001*
Urban 36(72%) 0
Rural 14(28%) 20(100%)
Smoking 0.01*
No 34 (68%) 20(100%)
Mild 6 (12%)
Severe 10 (20%)
DM 16 (32%) 5(25%) 0.2
WBCs 6.8 ± 2.9 5.2 ± 0.8 0.03*
Lymphocyte 1.8 ± 0.6 1.9 ± 0.4 0.4
HB 9.4 ± 2.3 12.8 ± 1.7 0.001*
TST I 0.009*
No reaction 40 (80%) 7(35%)
Negative 8 (16%) 12(60%)
Positive 2(4%) 1(5%)
TST II 0.005*
No reaction 30(60%) 6(30%)
Negative 12(24%) 13(65%)
Positive 8(16%) 1(5%)
QFT-IT 0.002*
Negative 26(56%) 20(100%)
Intermediate 14(28%)
Positive 10(20%)
* P< 0.05 = signiﬁcant.
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The QFT-GIT test will be performed according to the recom-
mendations of the manufacturer ((Quantiferon-TB Gold (in
tube method), Cellestis, Germany) [7]. The judgment was per-
formed according to the guidelines proposed by the Centers
for Disease Control and Prevention for using the QFT-TB test
[6].
It is performed in two stages. First; whole blood is collected
into each of the 3 Quantiferon-TB Gold collection tubes; one
containing heparin alone (the nil tube, or the negative control);
one containing the T cell mitogen phytohemagglutinin (the
mitogen tube, or the positive control); and one containing
the MTB-speciﬁc antigens ESAT-6, CFP-10, and TB7.7 (the
TB antigen tube).
The tubes were vigorously shacked for 5 s (or 10 times) till
frothing to ensure that the entire inner surface of the tube has
been coated with blood. The tubes were incubated at 37 C
incubator as soon as possible, and within 16 h of collection.
Incubation of the blood occurs in the tubes for 16 to 24 h, after
which plasma is harvested by centrifugation and then stored
frozen at 20 C until further analysis within 5 days. The
amount of IFN-y measured by enzyme- linked immunosorbent
assay (ELISA). Results were calculated using the QFT-IT soft-
ware provided by the manufacturer.
A low response to Mitogen < 0.5 IU/mL indicates an inde-
terminate result when a blood sample also has a negative
response to the TB antigens. This pattern may occur with
insufﬁcient lymphocytes, reduced lymphocyte activity due to
improper specimen handling, incorrect ﬁlling/mixing of the
mitogen tube, or inability of the patient‘s lymphocytes to gen-
erate IFN-y. The Nil sample adjusts for background, hetero-
phile antibody effects, or non-speciﬁc IFN-gama in blood
samples. The IFN-y level of the nil tube is subtracted from
the IFN-y level for the TB Antigen tube and Mitogen tube
(if used).
Statistical methods
Data entry and analysis were all done with I.B.M. compatible
computer using software called SPSS (Statistical Package for
social science) for windows version 13(SPSS, Inc., Chicago,
IL. Quantitative data were presented by mean and standard
deviation, while qualitative data were presented by frequency
distribution.
Mann–whitney test and Kruskal–wallis used to test the
signiﬁcant differences regarding quantitative data and Chi
square, z test and ﬁsher exact was used to test the signiﬁcant
differences regarding qualitative data. Correlation test was
used to test the association between quantitative data.
Univariate and multivariate logistic regression analyses
were performed to determine which factors were associated
with the TST and QFT-IT results. For the multivariate logistic
regression analysis, 2 different models were used: one based on
the MELD score and another based on the CPT classiﬁcation.
The agreement between tests was calculated with KAPPA
test. Poor agreement was deﬁned as a j value < 0.4, fair
agreement was deﬁned as a j value of 0.4 to 0.7, and excellent
agreement was deﬁned as a j value > 0.7.
All statistical analyses were 2-tailed, and a P value < 0.05
was considered statistically signiﬁcant.Results
A total of 50 patients with different types of cancer and 20
subjects as a healthy control were investigated for latent TB
in the period between January 2014 and September 2014.
Their demographic and clinical characteristics are shown in
Table 1. Regarding the underlying malignant diseases among
these patients, there were 20/50(40%) patients with hematolog-
ical malignancies, cancer breast was diagnosed in 8(16%)
patients. Ten patients (20%) had gastrointestinal malignancy,
8% presented with brain tumors, and 16% had other types
of malignancy. All of these patients receive chemotherapy
and/or radiotherapy. The mean age of cancer patients was
40.2 years. Twenty-eight (56%) of them were female, 16
(32%) were diabetic. Cancer patients had a signiﬁcantly higher
smoking history, lower Hb level in comparison with the
control group. A scar of BCG vaccination was present in 26
(52%) patients. General and local clinical examination of the
subjects revealed no signiﬁcant abnormality.
The results of TST I, TST II and GTF-GIT are signiﬁcantly
higher in cancer patients than in the control group.
A positive TSTI result was found only in 2 patients (4%).
On doing TSTII (booster phenomena) after 4 weeks, the num-
ber of patients with positive reaction increased to 8(16%)
patients (Table 1). The results of TST I and, TST II were
signiﬁcantly higher in cancer patients than in control.
Table 3 Distribution of Indeterminate results according to
lymphocyte counts and type of malignancies.
Variable Indeterminate
N= 14(28%)
Determinate
N= 36(72%)
P value
Lymphocyte count 0.001*
<1000 cells/mm3 6(42.9%) 0(0.0%)
>1000 cells/mm3 8(57.1%) 36(100%)
Type of malignancy 0.7
Hematological 6(42.9%) 14(38.9%)
Other cancers 8(57.1%) 22(61.1%)
* P< 0.05 = signiﬁcant.
684 H.A. Mohammad et al.Among the 50 patients who underwent the QFT-TB test,
ten subjects (20%) showed positive Quantiferon test, 26 sub-
jects (52%) showed a negative test while the test was indetermi-
nate in 14 patients (28%) (Table 1). As expected, the overall
rate of the result in cancer patients was signiﬁcantly higher
than in the control group (p< 0,005).
The distribution between the TSTI, TSTII results and the
QFT-TB test results in all patients is shown in Table 2.
Positive QFT-TB test results were signiﬁcantly more frequent
in patients with a negative TSTI-result (60%) (p= 0.001).
There was a statistically signiﬁcant association between
Quantiferon and TSTII; six cases with positive tuberculin
showed positive Quantiferon and an increase in the number
of cases who had both of +ve TSTII and +ve QFT. It was
noted that, 10/14 of the indeterminate QFT-IT results
(87.5%) were negative using TSTII.
About 42.9% of patients with indeterminate QFT reactions
had a signiﬁcant low lymphocytic count (<1000) and the same
percent of them had only Hematological Malignancy
(Table 3).
On univariate analysis (Table 4), patients with a history of
contact to active TB case had the highest and most signiﬁcant
proportion of positive QFT-TB results (odds ratio (OR) 19,
P= .0.009) followed by Diabetes mellitus: OR 4.5, P= 0.04
compared with patients with other risk factors for TB
(radiotherapy, smoking; (OR = 4.8, P= 0.06). Regarding,
TST II univariate analysis (Table 4), history of contact with
active TB case, diabetes, and patients who presented with
hematological malignancy were signiﬁcant predictors to have
active TB OR= 5.9, P= 0.04.
On multivariate analysis (not demonstrated) showed also,
that patients who had a positive history of close contact to
active TB cases, had similar and the highest signiﬁcant propor-
tion of positive QFT-TB results (OR = 26.8, P= 0.009) and
TSTII results (OR = 25.3, P= 0.01) followed by DM
(TSTII OR = 3.4, P= 0.03).
Hematological malignancy group (HMgroup) had signiﬁ-
cantly more positive TSTII results followed by the breast can-
cer group (P= 0.01). In addition, QFT-GOLD positive values
were more frequent in the HM group, however, was not signif-
icant. Signiﬁcantly fewer persons were identiﬁed as latently
infected by any test in GIT, and other cancer groups
Considering those patients with at least one positive test result
to be infected (Table 5).Table 2 Association between TST I, TST II and Quantiferon
test results in patient group.
TST Quantiferone test p
Negative
N = 26
Intermediate
N = 14
Positive
N = 10
TST I 0.001*
No reaction 26(100%) 12(86.7%) 2(20%)
Negative 0 2(14.3%) 6(60%)
Positive 0 0 2(20%)
TST II 0.001*
No reaction 24(92.3%) 4(26.8%) 2(20%)
Negative 2(7.7%) 10(71.2%) 0
Positive 0 0 8(80%)
* P< 0.05 = signiﬁcant.In Table 6: median lymphocyte counts showed signiﬁcant
negative correlation with positive QFT-GOLD results;
(P= 0.02) and median total leukocyte counts were also nega-
tively correlated with positive TSTII patients, meanwhile,
Diabetes mellitus and a history of close contact were positively
correlated in patients with positive TST II and also in those
with positive QFT-GOLD results.
Table 7 showed Kappa agreement between tests, there was
a poor agreement between QFT-GOLD and TSTI results
(k= 0.25, P= 0.007) meanwhile, a strong agreement was
found between QFT-GOLD and TSTII results (k= 0.72,
P= 0.001).
Discussion
The present study evaluated the accuracy of the results of
QTF -GIT test compared to those of TST during screening
of LTBI in 50 immunocompromised cancer patients in a hos-
pital-based population.
This study revealed that QTF GIT test was more sensitive
in detecting M. tuberculosis infection in patients with malig-
nancy than the TST. This supports previous observations that
demonstrated improved sensitivity in some immunosuppressed
subpopulations using the QTF GIT [8,9]. In our work, it was
noted an increase in sensitivity on repeating TST (2-step
TST). Some people infected with M. tuberculosis may have a
negative reaction to the TST if many years have passed since
they became infected, estimated at 8% per year [10]. They
may have a positive reaction to a subsequent TST because
the initial test may stimulate the immune system to produce
a true positive response, indicating a past infection. The boos-
ter phenomenon may occur at any age, but is more common in
older persons [6].
However, in the study of Susana et al. [11], only 4 patients
(7.3%) of the who’s ﬁrst TST results were negative and had
positive results with the second test, 2 of them were vaccinated
with the BCG vaccine and had negative QTF GIT results. This
suggests that some of the TST results may be false positives.
In our study, there was a poor agreement between QTF
GIT and TSTI results (k= 0.25, P= 0.007) meanwhile, a
moderate agreement was found between QTF GIT and
TSTII results (k= 0.72, P= 0.001). Considering all versions
of Quantiferon in different studies, discordant positive QFT
and negative TST results have been reported at a range varying
from 1% to 11% of all tested subjects [9].
Similar results noted by Nakaoka et al. [12], showing a
greater sensitivity for QFT GIT, but in all previous studies
the 2 step TST (TST II) has not been performed.
Table 4 Univariate analysis of patient characteristics and prediction of TB.
Variable QFT-IT TSTI TSTII
Odds ratio (95%CI) P Odds ratio (95%CI) P Odds ratio (95%CI) P
Age (yr) 1.02(0.97–1.06) 0.1 1.03(0.9–1.1) 0.4 1.03(0.9–1.1) 0.1
Male Sex 2.01(0.64–6.3) 0.2 5.6(0–7.6) 0.8 2.7(0.4–15) 0.2
Disease group
HM 2.7(0.6–11.5) 0.1 0.001(0–6.7) 0.8 5.9(1.1–33) 0.04*
Breast carcinoma 0.73(0.18–3.01) 0.7 4.9(0–6.2) 0.1 1.4(0.2–8.3) 0.7
GIT 0.50(0.12–1.9) 0.3 0.001(0–1.6) 0.8 0.001(0–3.2) 0.8
Others 0.54(0.09–3.3) 0.5 0.001(0–9.4) 0.9 0.001(0–1.9) 0.8
Medication
Less 3 1(0.1–5.6) 0.9 0.001(0–1.1) 0.8 1.4(0.2–8.3) 0.7
More than 3 1(0.1–5.6) 0.9 1.4(0–2.3) 0.9 0.7(0.1–4.1) 0.7
Radiotherapy 4.8(0.9–25.9) 0.06 6.1(0–7) 0.8 1.1(0–4.2) 0.6
Risk factors
Smoking 0.46(0.08–2.4) 0.3 0.001(0–9.3) 0.9 0.6(1–3.7) 0.6
DM 4.5(1.05–19.2) 0.04* 2.8(0–4.3) 0.8 9.5(1.6–55.2) 0.01*
History of contact 19(2.8–125.3) 0.009* 6.9(0.3–127.2) 0.1 13(2.1–79) 0.001*
Continuous variables
Erythrocyte count 1.04(0.4–2.7) 0.9 2.001(0–3) 0.9 1.1(0.3–3.4) 0.7
Leukocyte count 0.91(0.7–1.1) 0.4 0.9(0.5–1.5) 0.7 0.6(0.4–1.1) 0.05
Lymphocyte count 0.34(0.1–1.1) 0.09 0.2(0.01–3.4) 0.2 0.5(0.1–1.7) 0.2
Length of illness ms 0.75(0.2–2.5) 0.5 0.7(0.09–6.5) 0.8 0.7(0.2–2.3) 0.6
BCG 0.66(0.16–2.7) 0.5 0.001(0–1.8) 0.8 1.1(0.2–4.9) 0.9
* P< 0.05 = signiﬁcant.
Table 5 Results of TST and QFT-IT in the different groups of cancer patients.
Assay Results Hematologic N= 20 Breast N= 8 GIT N= 10 Others N= 12 P
TST I 0.005*
No reaction 12(60%) 6(75%) 10(100%) 8(100%)
Negative 8(40%) 0 0 4
Positive 0 2(25%) 0 0
TST II 0.01*
No reaction 8(40%) 6(75%) 8 8(66.5%)
Negative 6(30%) 0 2 4 (33.5 %
Positive 6(30%) 2(25%) 0 0
QFT-IT 0.1
Negative 8(40%) 6(75%) 6(60%) 10(83.3%)
Intermediate 6(30%) 0 2(20%) 2(16.7%)
Positive 6(30%) 2(25%) 2(20%) 0
* P< 0.05 = signiﬁcant.
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dant results in our population, as none of the considered vari-
ables (including age, sex) was signiﬁcantly associated with
disagreement between the two tests. In addition, errors in the
administration and reading of TST cannot be excluded, even
though by trained personnel as subjectivity is one of TST’s
main limitations. The presence of immunosuppression could
also inﬂuence TST and QFT results, even if only a few studies
are available [13].
Some reports have suggested that QFT assays might be
affected by a boosting effect when performed after TST [14].
This was not the case in our study as the two tests were admin-
istered at the same time.Some investigations asserted that the agreement between
TST and QFT was not very high because of the increased TST
positivity related with BCG vaccination or higher prevalence
of infection in certain populations. Low level agreement might
also be resulted from the elderly participants in those studies
who often had decreased TST positivity [15–17]. In parallel with
those reports, high level of agreement between the results of TST
and QFT was established in the unvaccinated individuals and
the populations with lower prevalence of tuberculosis [15,17].
It has frequently been suggested that use of IGRAs in
immunosuppressed individuals is commonly associated with
a high percentage of invalid results and that especially the
QFT test is hereby negatively affected [18–20].
Table 6 Correlation between TSTI, TSTII and QFT-IT and
risk factors.
Variables TSTI r(p) TSTII r(p) QFT-IT r(p)
Smoking 0.14(0.3) 0.06(0.6) 0.12(0.3)
DM 0.29(0.03)* 0.40(0.004)* 0.30(0.03)*
Contact to TB case 0.21(0.1) 0.45(0.001)* 0.51(0.001)*
Lymphocytic count 0.14(0.3) 0.19(0.1) 0.38(0.02)*
HB 0.25(0.07) 0.12(0.4) 0.25(0.08)
Leukocytic count 0.05(0.6) 0.36(0.009)* 0.19(0.1)
* P< 0.05 = signiﬁcant.
Table 7 Agreement between Quantiferon and Tuberculin
(Kappa test).
Kappa value p
TSTI 0.25 0.007*
TSTII 0.72 0.001*
* P< 0.05 = signiﬁcant.
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nized in 28% of our patients (14/50) which is more common
than that for control, 10 of the indeterminate QFT-GIT results
(87.5%) were negative using TSTII.
In previous reports, Ferrara et al. [21] noted a similar percent-
age (21%) and that these indeterminate results were signiﬁcantly
overrepresented among patients receiving immunosuppressive
treatments.
In other studies [22,23], indeterminate result for the QFT-
GIT test was recognized in lower percentage and it appeared
most frequently in patients receiving immunosuppressive treat-
ments who presented with lymphocytopaenia (especially CD4
lymphocytopaenia).
There is no doubt that the indeterminate result for any of
the IGRAs are largely the result of two different factors: a high
level of immunosuppression and/or technical error in blood
collection and handling or assay performance [24].
In our study, among possible explanations were low lym-
phocyte counts (<1000) that have been shown to increase
indeterminate IGRA results.
The QFT-GIT test depends on the elaboration of
inﬂammatory cytokines by T-cells previously sensitized to
MTB-speciﬁc antigens. In the blood, mononuclear cells from
peripheral blood are stimulated in vitro, and the production
of IFN-c from sensitized T-lymphocytes by MTB-speciﬁc anti-
gen is measured by ELISA in the QFT-GIT test [4]. Therefore,
it was ﬁrst speculated that lymphocytopaenia caused a
decreased production of IFN-c and lower mitogen, ESAT-6
or CFP-10 QFT-TB levels. Secondly, immunosuppressive
drugs, such as corticosteroid drugs, directly reduce the produc-
tion of inﬂammatory cytokines, such as IFN-c, interleukin-1
and TNF-a from T-lymphocytes [26,27]. Finally, the decrease
of IFN-c induced indeterminate results of the QFT-GIT test
because of the lower mitogen, ESAT-6 or CFP-10 QFT-TB
levels. This new IFN-c release assay including MTB-speciﬁc
antigen (TB 7.7; QuantiFERON TB-Gold In-Tube; Cellestis
Ltd.) [28] which was used in this work, has recently been
developed and replace the QFT-TB-2G test. However,immunosuppression was strongly associated with indetermi-
nate results for each of the two commercially available assays
[29].
Our results were not inﬂuenced by HIV-related immuno-
suppression as all HIV-positive subjects were excluded from
the analysis, but other causes of immunodeﬁciency, such as
anti-neoplastic drugs, radiotherapy and DM cannot be
excluded. The present interpretation showed a signiﬁcant
association between TST-positive/IGRA-positive results and
history of contact to the active case followed by Diabetes mel-
litus. Hematological malignancy has been associated with sig-
niﬁcantly more positive TSTII results compared with other
types of malignancy reﬂecting known risk factors of LTBI.
Despite the heterogeneity of the immunological substrate
presented depending on the speciﬁc type of malignancy,
patients with HM have an underlying immunological deﬁ-
ciency that facilitates the emergence of infections [30].
Alteration in the Th1 cell response of the HM itself or that
caused by antineoplastic chemotherapy or hematopoietic stem
cell transplantation (frequently associated with the administra-
tion of high doses of corticosteroids) lead to an impaired
immune response that particularly promotes the progression
from LTBI to active TB [31,32]. The risk of acquiring TB dis-
ease may correlate partly with the patient’s absolute neutrophil
counts; recent research on human neutrophil peptides has
highlighted their bactericidal action against TB and suggested
that neutrophils may play a more important defensive role in
tuberculosis [33].
A correlation between lymphocyte count and IFN-c
response was expected and this in consistent with the results
published by Kobashi et al. [34]. Further studies are needed
to evaluate the effect of low hemoglobin levels on patients with
malignancy associated IFN-c response in the QTF test.
In our study, it was found that the positivity of TST and
QFT were not increased with age.
In one of the studies [35,36] that evaluated the concomitant
positivity of TST and QFT, it was found that the positivity of
TST was associated with age and the positivity of QFT was
associated with working time [36]. Lange et al. [22] found that
positive QTF-GIT result was signiﬁcantly inﬂuenced by immi-
gration status and old age (p, 0.05) reﬂecting known risk fac-
tors of LTBI in Germany.
Many studies suggest that interferon gamma assays have
higher speciﬁcity than TST, and are less inﬂuenced by previous
BCG vaccination [35,37,38,25]. While in our study, both TST-
positive/IGRA- positive results were not affected by previous
BCG vaccination.
Conclusion
In summary, the main application of TST either in one step or
two step is to detect LTBI, but its role alone for evaluating the
risk for progression to disease is limited. Indeed, a signiﬁcant
increase in the rate of positive TST after one or two booster
injections has been reported. However, the problem of the
low speciﬁcity of the TST is not improved by booster injec-
tions. It must be interpreted in light of the clinical situation
and epidemiological history to allow for evaluation of risk of
disease. Parallel with these studies, it was found in our study
that QFT was more accurate for detection of LTBI in the
countries with routine BCG vaccination program.
Detection of LTBI in cancer patients 687The present ﬁndings support the conclusion that QFT-GIT
test provides more accurate results than TST in immunocom-
promised patients.
Recommendation
Immunocompromised individuals including cancer patients
should be evaluated regularly and treated for LTBI at the time
of diagnosis or just before starting immunosuppressive
treatment.
Also, in Egypt, almost all patients with malignant diseases
have a past history of BCG vaccination as BCG vaccination is
compulsory in Egypt. This increases the false positive rate of
the tuberculin test. In place of the TST test in vivo, the
QFT-GIT test in vitro is recommended in addition to TST
for patients suspected as having latent TB infection because
the QFT-GIT test demonstrated a negative result for BCG-
vaccinated individuals and a negative result for most NTM.
As interferon gamma assays are an important step in the
search for better diagnostic tests for latent TB. However, more
research is required to improve their performance, especially in
immunocompromised patients. Longitudinal studies are also
needed to assess the value of these tests in predicting the devel-
opment of active TB and to demonstrate clearly their superior-
ity to the TST.
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